Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma Biotechnology - Updates, News, Events, Signals & Triggers
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology Surging
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Puma Biotechnology, Inc.
PumaBiotech (@pumabiotech) / Twitter
Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals | Seeking Alpha
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Here's Why Puma Biotechnology Fell 17.2% in April | The Motley Fool
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Alan H. Auerbach - Los Angeles Business Journal
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
